Clin2
NCT07482020Possibly a fitRecruiting

SGLT2 inhibitor for atrial fibrillation, high blood pressure, and high blood sugar

Atrial Fibrillation (AF)Hypertension

Part of Heart & circulation clinical trials.

This study tests whether a medication called an SGLT2 inhibitor (a type of diabetes drug) can improve the function of the upper left heart chamber in people who have paroxysmal atrial fibrillation, high blood pressure, and abnormal blood sugar levels. If you qualify, the trial may help your heart work better and reduce your risk of stroke.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
66 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You are between 18 and 80 years old.
  • You have been diagnosed with paroxysmal atrial fibrillation (a type of irregular heartbeat that comes and goes).
  • You have high blood pressure and are already taking medication for it.
  • You either have diabetes and are taking medication for it, or you have prediabetes (HbA1c between 6.1% and 6.4%) without needing medication yet.
  • You do not have heart failure, severe valve problems, or certain types of cardiomyopathy.
  • You are not pregnant.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07331727Not yet recruiting
Dapagliflozin for atrial fibrillation before ablation

This study tests whether a medicine called dapagliflozin can reduce abnormal electrical activity in the heart by targeting fat around the heart in people with atrial fibrillation who are scheduled for a first catheter ablation. It may help improve the success of the procedure.

Shanghai
NCT06055452Recruiting· Phase 4
SGLT2 Inhibitors for Pre-Heart Failure with Hypertension

This trial tests if a medicine (SGLT2 inhibitor) given to people with high blood pressure and early signs of heart stress can help prevent heart failure. You may join if your blood pressure is controlled but tests show your heart is beginning to struggle.

Beijing, Beijing Municipality
NCT07187570Recruiting· Phase 3
Dapagliflozin to prevent atrial fibrillation recurrence after cardioversion

This trial tests if the diabetes drug dapagliflozin can lower the chance of atrial fibrillation (an irregular heartbeat) coming back after a procedure called electrical cardioversion, which uses a shock to restore a normal heart rhythm. If you have AF and are scheduled for cardioversion, you may be able to join.

Linköping
NCT06740786Not yet recruiting
Dapagliflozin to prevent AF recurrence after ablation

This trial tests if dapagliflozin, a medication for diabetes and heart failure, can help prevent atrial fibrillation from returning after your first catheter ablation procedure for AF.

NCT05029115Enrolling by invitation
SGLT2 pill study for atrial fibrillation with type 2 diabetes

This trial tests whether an SGLT2 inhibitor pill can help people who have atrial fibrillation (an irregular heartbeat) and type 2 diabetes. You may be eligible if you’re in the right age range, on diabetes pills only, and meet specific heart and lab criteria.

Yangcheon, Seoul
NCT07186153Not yet recruiting
Study of a diabetes drug on heart changes in diabetic patients

This study tests whether a type of diabetes medication called an SGLT2 inhibitor can improve the structure and function of the heart's left atrium in people with type 2 diabetes. It may help prevent heart problems in the future.

Hear when a new High blood pressure trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.